Comparing Silverback Therapeutics (NASDAQ:SBTX) & GeoVax Labs (NASDAQ:GOVX)

GeoVax Labs (NASDAQ:GOVX) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Profitability

This table compares GeoVax Labs and Silverback Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeoVax Labs	N/A	-809.87%	-349.34%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Insider and Institutional Ownership

6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

GeoVax Labs has a beta of 3.24, meaning that its share price is 224% more volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for GeoVax Labs and Silverback Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeoVax Labs	0	0	5	2	3.29
Silverback Therapeutics	0	0	0	0	0.00

GeoVax Labs currently has a consensus target price of $14.20, indicating a potential upside of 437.88%. Given GeoVax Labs’ stronger consensus rating and higher probable upside, equities analysts plainly believe GeoVax Labs is more favorable than Silverback Therapeutics.

Valuation & Earnings

This table compares GeoVax Labs and Silverback Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeoVax Labs	$3.09 million	8.06	-$25.97 million	N/A	N/A
Silverback Therapeutics	N/A	N/A	-$89.48 million	($2.42)	-4.43

GeoVax Labs has higher revenue and earnings than Silverback Therapeutics.

Summary

GeoVax Labs beats Silverback Therapeutics on 7 of the 11 factors compared between the two stocks.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

About Silverback Therapeutics

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.